Platelet-Rich Plasma and Hip Osteoarthritis

The Effect of Platelet-Rich Plasma Injection on Pain, Function and Quality of Life in Patients With Hip Osteoarthritis

To evaluate the effect of platelet-rich plasma (PRP) injection on pain, function and quality of life in patients with hip osteoarthritis.

After being informed about the study and potential risk, all patients giving written informed consent will undergo study entry.

Each patient received three times intra-articuler injections of PRP under ultrasound guidance, and they were administered once a week.

Baseline: Visual Analog Scale (VAS) including movement, rest and night, the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) and SF-36 assessment

1st month: VAS, WOMAC and SF-36 assessment

3rd month: VAS, WOMAC and SF-36 assessment

6th month: VAS, WOMAC and SF-36 assessment

Inclusion Criteria:

• Hip pain VAS > 4
• Grade 1 and 2 osteoarthritis according to the Kellgren-Lawrence classification
• No pathologies in the laboratory and coagulation parameters

Exclusion Criteria:

• Rheumatological disease with hip involvement
• Systemic active infection
• Severe cardiovascular disease
• Malignancy
• NSAID usage in the last week
• History of hip joint surgery
• History of traumatic hip injury
• Hgb values < 11 gr/dl
• Platelets values < 150.000 / µl
• History of bleeding disorder